Stockscreener 앱 받기
1.82
8.34%
0.13
전일 마감가:
$1.69
열려 있는:
$1.71
하루 거래량:
547.81K
Relative Volume:
0.66
시가총액:
$373.46M
수익:
$893.00K
순이익/손실:
$-151.61M
주가수익비율:
-3.5326
EPS:
-0.5152
순현금흐름:
$-135.31M
1주 성능:
+8.34%
1개월 성능:
-1.56%
6개월 성능:
-13.63%
1년 성능:
+150.82%
1일 변동 폭
$1.68
$1.845
1주일 범위
$1.59
$1.845
52주 변동 폭
$0.54
$7.13
Prokidney Corp Stock (PROK) Company Profile
명칭
Prokidney Corp
전화
336-999-7028
주소
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
1.82 | 346.79M | 893.00K | -151.61M | -135.31M | -0.5152 |
VRTX
Vertex Pharmaceuticals Inc
|
438.34 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
626.35 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
824.27 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.52 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.27 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-16 | 개시 | H.C. Wainwright | Buy |
| 2025-06-30 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-09-30 | 개시 | JP Morgan | Neutral |
| 2024-09-10 | 개시 | Guggenheim | Buy |
| 2024-03-07 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-01-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-07-25 | 개시 | BTIG Research | Buy |
| 2022-12-21 | 개시 | Jefferies | Buy |
| 2022-11-10 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-10-18 | 개시 | UBS | Buy |
| 2022-10-14 | 개시 | Citigroup | Buy |
| 2022-09-23 | 개시 | BofA Securities | Buy |
| 2022-09-02 | 개시 | Evercore ISI | Outperform |
모두보기
Prokidney Corp 주식(PROK)의 최신 뉴스
Number of shareholders of ProKidney Corp. – NASDAQ:PROK - TradingView
PROK Technical Analysis | Trend, Signals & Chart Patterns | PROKIDNEY CORP (NASDAQ:PROK) - ChartMill
PROK Reiterated by HC Wainwright & Co. -- Price Target Maintained at $12 - GuruFocus
Analyst Maintains Sell on ProKidney Amid Single-Asset Risk and Long Path to 2028 BLA, Keeps $1 Price Target Below Market - TipRanks
ProKidney's first-quarter loss grows with increased operating expenses - Winston-Salem Journal
ProKidney Corp. (PROK) reports Q1 loss, tops revenue estimates - MSN
ProKidney Releases Q1 2026 Financial Results - AlphaStreet
Prokidney Corp reports results for the quarter ended March 31Earnings Summary - TradingView
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
ProKidney reports Q1 EPS (14c), consensus (14c) - TipRanks
ProKidney Highlights Progress in Pivotal Phase 3 CKD Trial - TipRanks
ProKidney Q1 loss widens as R&D spending rises - TradingView
PROKIDNEY CORP. 1Q 2026: Revenue $0.226M, EPS $(0.14) — 10-Q Summary - TradingView
PROK: Phase 3 trial enrollment on track; cash runway extends into mid-2027 amid rising R&D costs - TradingView
ProKidney Corp. Reports Phase 3 PROACT 1 Study Enrollment Progress and Q1 2026 Financial Results - Quiver Quantitative
PROK: Net loss widened to $42.6M in Q1 2026 as R&D spending rose for Phase 3 trials - TradingView
[8-K] PROKIDNEY CORP. Reports Material Event - Stock Titan
ProKidney (NASDAQ: PROK) Q1 2026 loss, R&D spend and cash runway to 2027 - Stock Titan
Kidney disease cell therapy ProKidney eyes key 2027 trial results - Stock Titan
BRIEF-ProKidney Q1 Operating Income USD -44.933 Million - TradingView
Press Release: ProKidney Reports First Quarter 2026 Financial Results and Business Highlights - Moomoo
TradingKey - TradingKey
PROKIDNEY CP (PROK) Eps Diluted (TTM) - Zacks Investment Research
ProKidney Corp. (NASDAQ:PROK) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
3 Promising Penny Stocks With Market Caps Up To $600M - Sahm
ProKidney (PROK) to Release Quarterly Earnings on Monday - MarketBeat
ProKidney approaches pivotal research, funding crossroads for drug therapy - Winston-Salem Journal
ProKidney Names Greg Madison as Chief Commercial Officer - HarianBasis.co
PROK - Finviz
ProKidney (PROK) Appoints Greg Madison as CCO to Lead Commercial Strategy for Rilparencel - Insider Monkey
[SCHEDULE 13D/A] PROKIDNEY CORP. Amended Major Shareholder Report - Stock Titan
Control Empresarial converts 63.1M PROK (NASDAQ: PROK) Paired Interests into Class A shares - Stock Titan
Culleton - Winston-Salem Journal
9 Best Biotech Penny Stocks to Buy in 2026 - Insider Monkey
MSN Money - MSN
ProKidney spikes after mid-stage trial data for lead asset - MSN
ProKidney's top executive gains nearly threefold hike in 2025 compensation - Winston-Salem Journal
ProKidney (PROK) Stock Live Trade (On the Radar) 2026-04-20Late Breakout - Cổng thông tin điện tử tỉnh Lào Cai
ProKidney (NASDAQ:PROK) Upgraded to Sell at Wall Street Zen - MarketBeat
ProKidney (NASDAQ:PROK) Stock Price Up 9%Should You Buy? - MarketBeat
Executive pay, governance on agenda at ProKidney (NASDAQ: PROK) vote - Stock Titan
ProKidney Corp. (NASDAQ:PROK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
ProKidney (PROK) Stock: Trend Strength (Buying Pressure) 2026-04-15AI Powered Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai
ProKidney (NASDAQ:PROK) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Bull Run: Can ProKidney Corp continue delivering strong returns2026 Key Highlights & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Winners Losers: Is ProKidney Corp impacted by rising rates2026 Market Sentiment & Fast Entry High Yield Stock Tips - baoquankhu1.vn
High stakes: ProKidney pushes toward commercialization as cash dwindles, opportunity awaits - The Business Journals
Is ProKidney (PROK) Stock suitable for dividend investors | Price at $1.88, Up 1.35%Expert Momentum Signals - Xã Châu Thành
Analysis Recap: Will ProKidney Corp benefit from government policyQuarterly Portfolio Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Can ProKidney (PROK) Stock Reach New Highs | Price at $1.81, Down 4.74%Social Buy Zones - Cổng thông tin điện tử tỉnh Lào Cai
April 2026 Penny Stock Highlights - Sahm
Prokidney Corp (PROK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.67%
1.91%
자본화:
|
볼륨(24시간):